FeesSafety
Pluang+

Emerging markets equities dip 0.37% in Q3 amid AI chip selloff and rising yields.

04 Nov 2026, 14:15 WIB
Seeking Alpha
View Source
Neutral
Emerging markets equities dip 0.37% in Q3 amid AI chip selloff and rising yields.

Emerging markets equities declined by 0.37% in the third quarter, with the Global X Emerging Markets Consumer ETF (EMC) slightly underperforming the MSCI Emerging Markets Index by 9 basis points. The quarter saw a selloff in AI chip stocks and rising yields, which offset gains in regions like Hong Kong and Latin America. EMC adjusted its holdings by adding Banco BTG Pactual, Bank Pekao, and Naura Technology, while selling Xiaomi, Tata Consultancy Services, and four smaller positions. This performance highlights the mixed pressures on emerging markets as investors navigate technology sector volatility and macroeconomic factors.

The Global X Emerging Markets Great Consumer ETF Q3 2026 commentary provides context for emerging markets. For readers following financials, here is Pluang's market snapshot as of Nov 04, 2026 16:11 WIB: of 142 priced Financials-sector US stocks tradable on Pluang, 71 rose and 60 fell today. ING was up 3.88% at USD 32.10 with 100% buy orders, AVAT rose 3.44% to USD 0.90, and BCS fell 3.35% to USD 23.15 with 100% sell orders.

More News

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...

Market News
Bearish
26 minutes ago
Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...

Company Fundamentals
Bullish
26 minutes ago
ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...

Market News
Bullish
26 minutes ago
New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...

Others
Bullish
26 minutes ago
Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...

Market News
Bullish
26 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App